Patent US4737487A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4737487A Expired / Lapsed US ⏱️ 0.0 years remaining

VIP type peptides

Assignee: Beecham Group PLC
•
Filing: 1985-10-31
•
Granted: 1988-04-12
•
Expires: 2005-10-31
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Peptides comprising, in sequence, units selected from the amino acid residues 11 to 23 of vasoactive intestinal peptide (VIP) and consisting at least of the amino acid residues 15 to 20, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent other amino acid, or a pharmaceutically acceptable salt thereof; having pharmacological activity, a process for their preparation and their use as pharmaceuticals.

Inventors

  • 👤 Eric A. Watts
  • 👤 Gordon Wootton
  • 👤 Christine Summers

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 14:16
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/57563; A; A61; A61P; A61P11/00; A61P11/08; A61P9/00; A61P9/08; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/17

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 292 words
A polypeptide of the general formula X--(Y').sub.n --Y.sub.15 Y.sub.16 Y.sub.17 Y.sub.18 Y.sub.19 Y.sub.20 --(Y").sub.m --Z in which X represents a hydrogen atom or an amine-protecting group, preferably a hydrogen atom; (Y') n represents a direct bond or Y.sub.11 Y.sub.12 Y.sub.13 Y.sub.14, Y.sub.12 Y.sub.13 Y.sub.14, Y.sub.13 Y.sub.14 or Y.sub.14 in which Y 11 represents Thr, Ser or the residue of another naturally occurring hydroxy amino acid, Y 12 represents Arg or the residue of another naturally occurring basic amino acid, Y 13 represents Leu, Phe or the residue of another naturally occurring hydrophobic amino acid, Y 14 represents Arg or the residue of another naturally occurring basic amino acid; Y 15 represents Lys or the residue of another naturally occurring basic amino acid, Y 16 represents Gln or the residue of another naturally occurring carboxamido amino acid, Y 17 represents Met or the residue of another naturally occurring neutral amino acid, Y 18 represents Ala or the residue of another naturally occurring hydrophobic amino acid, Y 19 represents Val or the residue of another naturally occurring hydrophobic amino acid, Y 20 represents Lys or the residue of another basic naturally occurring amino acid, (Y") m represents a direct bond or Y.sub.21, Y.sub.21 Y.sub.22 or Y.sub.21 Y.sub.22 Y.sub.23 in which Y 21 represents Lys or the residue of another basic naturally occurring amino acid, Y 22 represents Tyr or the residue of another naturally occurring hydrophobic amino acid, Y 23 represents Leu or the residue of another naturally occurring hydrophobic amino acid; and Z represents a hydroxyl group, or a group of the formula OR such COZ represents an ester, or a hydrazino group such that COZ represents a hydrazide, or NH 2 such that COZ represents an amide; and pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim 292 words
A polypeptide of the general formula X--(Y').sub.n --Y.sub.15 Y.sub.16 Y.sub.17 Y.sub.18 Y.sub.19 Y.sub.20 --(Y").sub.m --Z in which X represents a hydrogen atom or an amine-protecting group, preferably a hydrogen atom; (Y') n represents a direct bond or Y.sub.11 Y.sub.12 Y.sub.13 Y.sub.14, Y.sub.12 Y.sub.13 Y.sub.14, Y.sub.13 Y.sub.14 or Y.sub.14 in which Y 11 represents Thr, Ser or the residue of another naturally occurring hydroxy amino acid, Y 12 represents Arg or the residue of another naturally occurring basic amino acid, Y 13 represents Leu, Phe or the residue of another naturally occurring hydrophobic amino acid, Y 14 represents Arg or the residue of another naturally occurring basic amino acid; Y 15 represents Lys or the residue of another naturally occurring basic amino acid, Y 16 represents Gln or the residue of another naturally occurring carboxamido amino acid, Y 17 represents Met or the residue of another naturally occurring neutral amino acid, Y 18 represents Ala or the residue of another naturally occurring hydrophobic amino acid, Y 19 represents Val or the residue of another naturally occurring hydrophobic amino acid, Y 20 represents Lys or the residue of another basic naturally occurring amino acid, (Y") m represents a direct bond or Y.sub.21, Y.sub.21 Y.sub.22 or Y.sub.21 Y.sub.22 Y.sub.23 in which Y 21 represents Lys or the residue of another basic naturally occurring amino acid, Y 22 represents Tyr or the residue of another naturally occurring hydrophobic amino acid, Y 23 represents Leu or the residue of another naturally occurring hydrophobic amino acid; and Z represents a hydroxyl group, or a group of the formula OR such COZ represents an ester, or a hydrazino group such that COZ represents a hydrazide, or NH 2 such that COZ represents an amide; and pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim 16 words
A peptide according to claim 1 wherein all the amino acid units are in the L-form.
Claim 4
Dependent Claim 24 words
A peptide or analogue according to claim 1 wherein the carboxy-terminus of the peptide or analogue is in the form of the unsubstituted amide.
Claim 5
Dependent Claim 22 words
A peptide or analogue according to claim 1 wherein the amino-terminus of the peptide is in the form of the unsubstituted amine.
Claim 6
Dependent Claim 14 words
The hexapeptide H-Lys-Gln-Y-Ala-Val-Lys-NH 2 or H-Lys-Gln-Y-Ala-Leu-Lys-NH 2 , wherein Y represents Met or Nle.
Claim 7
Dependent Claim 14 words
The hexapeptide H-Lys-Gln-Y-Ala-Val-Lys-NH 2 or H-Lys-Gln-Y-Ala-Leu-Lys-NH 2 , wherein Y represents Met or Nle.
Claim 8
Dependent Claim 44 words
H-Lys-Gln-Nle-Ala-Val-Lys-NH 2 , H-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 , H-Leu-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 , H-Lys-Gln-Nle-Ala-Leu-Lys-NH 2 , H-Lys-Gln-Nle-Ala-Val-Orn-NH 2 , H-Orn-Gln-Nle-Ala-Val-Orn-NH 2 , H-Lys-Gln-Leu-Ala-Val-Lys-NH 2 , H-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Nle-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 or ##STR9## or a pharmaceutically acceptable salt of any of the foregoing.
Claim 9
Dependent Claim 44 words
H-Lys-Gln-Nle-Ala-Val-Lys-NH 2 , H-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 , H-Leu-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 , H-Lys-Gln-Nle-Ala-Leu-Lys-NH 2 , H-Lys-Gln-Nle-Ala-Val-Orn-NH 2 , H-Orn-Gln-Nle-Ala-Val-Orn-NH 2 , H-Lys-Gln-Leu-Ala-Val-Lys-NH 2 , H-Arg-Lys-Gln-Nle-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Nle-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-NH 2 , H-Lys-Gln-Nle-Ala-Val-Lys-Lys-NH 2 or ##STR9## or a pharmaceutically acceptable salt of any of the foregoing.
Claim 10
Dependent Claim 10 words
A compound according to claim 1 in pharmaceutically acceptable form.
Claim 11
Dependent Claim 32 words
A pharmaceutical composition for treating peptic ulcer disease comprising an effective amount of a peptide or analogue according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim 37 words
A method of treatment of peptic ulcer disease disorders in mammals, such as humans which comprises the administration of an effective amount of a peptide or analogue according to claim 1, or a pharmaceutically acceptable salt thereof.

References Cited (Backward Citations)

US3898329A Cited
US3862927A Cited
US4016258A Cited
US4237046A Cited
US4605641A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-04-12 1991-10-12 1992-04-12 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-04-12 1995-10-12 1996-04-12 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-04-12 1999-10-12 2000-04-12 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag